New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - aciclovir 250mg - powder for infusion - 250 mg - active: aciclovir 250mg excipient: sodium hydroxide

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - metformin hydrochloride 250mg - coated tablet - 250 mg - active: metformin hydrochloride 250mg excipient: magnesium stearate opadry clear oy-29020 povidone water

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - choriogonadotropin alfa - injection, solution - 250 mcg - choriogonadotropin alfa 250 mcg

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

modern pharmaceutical company serbia - 250 ml glass bottle - infusion - 400 mg/ 250 ml - infections-antibacterial

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

alphamed drug store saudi arabia - 250ml bottle - inhalation - 250 ml - anaesthesia-general anaesthesia

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - atovaquone 250mg; proguanil hydrochloride 100mg - film coated tablet - active: atovaquone 250mg proguanil hydrochloride 100mg excipient: colloidal silicon dioxide hyprolose magnesium stearate microcrystalline cellulose opadry brown 03c86943 poloxamer sodium starch glycolate tolpovidone i 131 - promozio (250mg atovaquone/100mg proguanil hydrochloride) is indicated for: · prophylaxis of plasmodium falciparum malaria in adults · treatment of plasmodium falciparum malaria in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 250 [iu];   - injection with diluent - 250 iu - active: octocog alfa 250 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage); nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) - powder for injection with diluent - 250 iu - active: nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection sodium chloride water for injection active: nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefuroxime sodium 256mg equivalent to 250 mg cefuroxime anhydrous;   - powder for injection - 250 mg - active: cefuroxime sodium 256mg equivalent to 250 mg cefuroxime anhydrous  

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - factor viii inhibitor bypassing fraction 2500 u;  ;   - powder for injection with diluent - 2500 u - active: factor viii inhibitor bypassing fraction 2500 u     excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.